Thyroid Cancer Stages (AJCC 8th Edition (TNM))
Understanding what each stage means for your diagnosis, treatment options, and expected outcomes.
Reviewed by Oncology Team, HealOnco | Last updated: 2026-04
TNM 8th edition (AJCC) used; note that age at diagnosis (<55 vs. ≥55 years) dramatically impacts prognosis for papillary and follicular cancers (younger patients rarely develop Stage IV even with advanced local disease).
Staging Overview
| Stage | What It Means | 5-Year Survival* | Typical Treatment |
|---|---|---|---|
| Stage I (Papillary/Follicular, age <55 years) | Any T, any N, M0 (no distant metastases). Encompasses tumors <4 cm to large invasive tumors WITH nodal involvement, as long as no distant mets. Age <55 imparts significantly better prognosis. | 10-year survival >95%; recurrence-free survival 80–90% with multimodal therapy (surgery + RAI if indicated). | Near-total or total thyroidectomy; radioactive iodine ablation if intermediate/high-risk features (>1 cm, lymph node mets, extrathyroidal extension, or high-risk histology like tall-cell variant). TSH suppression with levothyroxine (target TSH 0.5–2.0 mIU/L) lifelong. Ultrasound and thyroglobulin monitoring annually for 5–10 years. |
| Stage I (Papillary/Follicular, age ≥55 years) | Tumors ≤4 cm, confined to thyroid (T1-T2), N0-N1a (central lymph nodes only), M0. | 10-year survival 90–95%; lower than age <55 due to comorbidities, competing mortality. | Near-total or total thyroidectomy ± RAI (individualize based on tumor size, histology, nodal involvement). TSH suppression less aggressive (target TSH 0.5–2.0 mIU/L) due to cardiac/bone toxicity risk in elderly. |
| Stage II (Papillary/Follicular, age ≥55 years) | Tumors >4 cm confined to thyroid (T3) OR any tumor with lateral lymph node metastases (N1b), no distant mets. Age ≥55 required for Stage II distinction. | 10-year survival 80–90%; extrathyroidal extension worsens outcomes. | Total thyroidectomy with lymph node dissection (central ± lateral if N1b); RAI ablation for T3, N1b, or both. TSH suppression moderate (target 0.1–0.5 mIU/L). More intensive surveillance (ultrasound, serum thyroglobulin every 6 months for 5 years). |
| Stage III (Papillary/Follicular, age ≥55 years) | Tumors with gross extrathyroidal extension (T4a: macroscopic infiltration of larynx, trachea, esophagus, recurrent laryngeal nerve), any N, M0. | 10-year survival 50–70%; depends on extent of invasion, resectability, nodal involvement. | Total thyroidectomy with en bloc resection of invaded structures (larynx, trachea segment, etc.) if feasible; RAI ablation post-surgery. External beam radiation therapy (EBRT) to neck/mediastinum often added (50–60 Gy) if high-risk features. TSH suppression intense (target TSH <0.1 mIU/L) to minimize progression. Chemotherapy (carboplatin-paclitaxel) for unresectable or rapidly progressive disease. |
| Stage IVA (Papillary/Follicular, age ≥55 years) | Intrathyroidal tumors (T4a) OR distant lymph node metastases (N1b at ≥55 years defines Stage IVA in some substaging systems), M0 (any T4b tumor = Stage IVB by definition, or M1). | 10-year survival 35–50%; prognosis worsens with distant spread. | Resection of primary + lymph node dissection if feasible. RAI ablation. EBRT for T4b (gross extrathyroidal extension). TSH suppression maximum (target TSH <0.1 mIU/L). Targeted therapy (lenvatinib, sorafenib) for radioactive iodine-refractory (RAIR) metastases. |
| Stage IVB (Papillary/Follicular) | Distant metastases (M1): pulmonary, osseous, brain, etc. | 10-year survival 10–40%; papillary with pulmonary mets more indolent (median OS >10 years); anaplastic with mets median OS <6 months. | RAI ablation if disease is RAI-avid (repeat 131-I therapy every 3–6 months if uptake present). TSH suppression maximum. Targeted therapy: lenvatinib (oral multi-tyrosine kinase inhibitor; improved OS in DECISION trial) 24 mg daily OR sorafenib (alternative TKI) 400 mg BID. Immunotherapy emerging (pembrolizumab for advanced/metastatic, especially if BRAF V600E+ or MSI-H, but limited data). Supportive care, bone metastases management, pain control. |
| Stage I–IV Medullary Thyroid Cancer (MTC) | MTC has different staging: Stage I: T1, N0, M0 (tumor <1 cm); Stage II: T2-T3, any N, M0 (tumor 1–4 cm or extrathyroidal extension); Stage III: T4a, any N, M0 (gross extrathyroidal extension); Stage IV: T4b, N1b, or M1. | Stage I: 10-year survival ~90%; Stage II: 70%; Stage III: 50%; Stage IV: 10–30%. Calcitonin doubling time (marker of disease progression) predicts survival. | Total thyroidectomy + central neck lymph node dissection (therapeutic/prophylactic). Lateral neck dissection if N1b suspected (calcitonin >100 pg/mL, imaging evidence). RAI not effective (C cells don’t take up iodine). EBRT for extrathyroidal extension. Chemotherapy (vandetanib, cabozantinib, lenvatinib) for metastatic disease. For MEN2 families: prophylactic thyroidectomy by age 10 (RET mutation carriers). |
| Stage I–IV Anaplastic Thyroid Cancer (ATC) | Anaplastic cancers are inherently aggressive; all are classified Stage IV per AJCC 8th edition (IVA: intrathyroidal; IVB: gross extrathyroidal extension; IVB: distant mets = same stage numerically). | Median overall survival untreated: 3–6 months; with aggressive multimodal therapy: 12–24 months in select patients. 5-year survival <5%. | Surgical resection if completely resectable (total thyroidectomy, lymph node dissection, en bloc resection of invaded structures). IMMEDIATE concurrent chemoradiation (50–60 Gy EBRT + carboplatin-paclitaxel) starting within days of surgery. Immunotherapy (nivolumab, pembrolizumab) for PD-L1+ disease or as consolidation. Molecular-directed therapy if actionable mutation (BRAF V600E inhibitor dabrafenib+trametinib, RAS/PI3K inhibitors). Palliative intent if unresectable. |
Note: age <55 years dramatically improves prognosis for papillary/follicular cancers (most Stage IV papillary in elderly patients classified as Stage I if age <55, due to low mortality risk from distant mets). Medullary and anaplastic cancers lack this age-based prognosis distinction and are inherently more aggressive.
Explore Each Stage
Stage I (Papillary/Follicular, age <55 years)Any T, any N, M0 (no distant metastases). Encompasses tumors <4 cm to large invasive tumors WITH…5-year survival: 10-year survival >95%; recurrence-free survival 80–90% with multimodal therapy (surgery + RAI if indicated).
Stage I (Papillary/Follicular, age ≥55 years)Tumors ≤4 cm, confined to thyroid (T1-T2), N0-N1a (central lymph nodes only), M0.5-year survival: 10-year survival 90–95%; lower than age <55 due to comorbidities, competing mortality.
Stage II (Papillary/Follicular, age ≥55 years)Tumors >4 cm confined to thyroid (T3) OR any tumor with lateral lymph node metastases (N1b), no…5-year survival: 10-year survival 80–90%; extrathyroidal extension worsens outcomes.
Stage III (Papillary/Follicular, age ≥55 years)Tumors with gross extrathyroidal extension (T4a: macroscopic infiltration of larynx, trachea,…5-year survival: 10-year survival 50–70%; depends on extent of invasion, resectability, nodal involvement.
Stage IVA (Papillary/Follicular, age ≥55 years)Intrathyroidal tumors (T4a) OR distant lymph node metastases (N1b at ≥55 years defines Stage IVA in…5-year survival: 10-year survival 35–50%; prognosis worsens with distant spread.
Stage IVB (Papillary/Follicular)Distant metastases (M1): pulmonary, osseous, brain, etc.5-year survival: 10-year survival 10–40%; papillary with pulmonary mets more indolent (median OS >10 years); anaplastic with mets median OS <6 months.
Stage I–IV Medullary Thyroid Cancer (MTC)MTC has different staging: Stage I: T1, N0, M0 (tumor <1 cm); Stage II: T2-T3, any N, M0 (tumor…5-year survival: Stage I: 10-year survival ~90%; Stage II: 70%; Stage III: 50%; Stage IV: 10–30%. Calcitonin doubling time (marker of disease progression) predicts survival.
Stage I–IV Anaplastic Thyroid Cancer (ATC)Anaplastic cancers are inherently aggressive; all are classified Stage IV per AJCC 8th edition…5-year survival: Median overall survival untreated: 3–6 months; with aggressive multimodal therapy: 12–24 months in select patients. 5-year survival <5%.
Why staging matters
Stage at diagnosis is the single strongest predictor of outcome. Early-stage thyroid cancer is often curable with surgery or localised treatment. Advanced stages require systemic therapy but still benefit from modern protocols. Knowing your stage helps your oncologist plan the most effective treatment path.
Need Help Understanding Your Stage?
Our oncology team can review your reports and explain what your stage means for treatment.
Talk to a Specialist